SAN DIEGO, April 29, 2011 /PRNewswire via COMTEX/ --
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report first quarter 2011 financial results on Friday, May 6, 2011
before the open of the financial markets. The announcement will be
followed by a conference call with the investment community at 8:00 a.m. PDT (11:00 a.m. EDT),
which will be simultaneously broadcast over the Internet. Management
will discuss the financial results and highlights for the first quarter
of 2011 and provide a product pipeline update.
(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)
To participate by telephone, please dial 877.407.8037 for domestic
callers or 201.689.8037 for international callers. Those interested in
listening to the conference call live via the Internet may do so by
visiting the Investor Relations section of the company's Web site at www.halozyme.com.
Shortly after the call an audio replay will be available on Halozyme's
Web site for seven days. A telephone replay will be available by dialing
877.660.6853 from the U.S., or 201.612.7415 for international callers
and using account # 367 and ID # 371588.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company developing and
commercializing products targeting the extracellular matrix for the
insulin, cancer, dermatology and drug delivery markets. The company's
product portfolio is based primarily on intellectual property covering
the family of human enzymes known as hyaluronidases and additional
enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM)
technology is a novel drug delivery platform designed to increase the
absorption and dispersion of biologics. The company has key partnerships
with Roche and Baxter to apply Enhanze technology to therapeutic biologics including Herceptin(R), MabThera(R),
and immunoglobulin. Halozyme's Ultrafast Insulin program combines its
rHuPH20 enzyme with mealtime insulins, which may produce more rapid
absorption, faster action, and improved glycemic control. The product
candidates in Halozyme's pipeline target multiple areas of significant
unmet medical need. For more information visit www.halozyme.com.
Halozyme Contact
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.com
SOURCE Halozyme Therapeutics, Inc.